Table 1 Baseline characteristics of kidney transplant and dialysis patients
Characteristic | Dialysis patients (n = 40) | Kidney transplant patients (n = 39) | P value |
|---|---|---|---|
Age, years, mean (s.d.) | 56 (11) | 47 (12) | 0.001 |
Sex, male | 28 (70) | 27 (69) | 0.57 |
BMI, kg/m2, mean (s.d.) | 26.7 (4.8) | 26.0 (4.6) | 0.60 |
Cardiovascular risk factors, n (%) | |||
 Hypertension | 37 (93) | 36 (92) | 0.65 |
 Diabetes | 17 (43) | 11 (28) | 0.14 |
 Dyslipidemia | 34 (85) | 27 (69) | 0.080 |
 Current smoking | 4 (10) | 2 (5.1) | 0.68 |
Cardiovascular disease | |||
 Myocardial infarction | 4 (10) | 2 (5.1) | 0.35 |
 Stroke | 3 (7.5) | 0 (0) | 0.13 |
 Heart failure | 2 (5.0) | 1 (2.6) | 0.51 |
 Percutaneous coronary intervention or bypass surgery | 4 (10) | 4 (10) | 1.00 |
Dialysis vintage, months, median (IQR) | 24 (15–42) | 14 (9–28) | 0.028 |
Cause of end-stage renal disease | Â | Â | 0.052 |
 Diabetes | 16 (40) | 9 (23) |  |
 Hypertension | 3 (7.5) | 3 (7.7) |  |
 Glomerulonephritis | 12 (30) | 8 (20) |  |
 Polycystic kidney disease | 2 (5.0) | 9 (23) |  |
 Interstitial nephritis | 2 (5.0) | 3 (7.7) |  |
 Congenital anomalies | 1 (2.5) | 3 (7.7) |  |
 Other/unknown | 4 (10) | 4 (10) |  |
Cardiovascular medications, n (%) | |||
 Beta-blockers | 19 (48) | 21 (54) | 0.37 |
 ACE inhibitors | 10 (25) | 10 (26) | 0.58 |
 ARB | 14 (35) | 11 (28) | 0.34 |
 CCB | 17 (43) | 24 (62) | 0.071 |
 Diuretic | 15 (38) | 11 (28) | 0.26 |
 Statin | 29 (73) | 17 (44) | 0.008 |
 Fibrate | 0 (0) | 1 (2.6) | 0.49 |
 Ezetimibe | 3 (7.5) | 2 (5.1) | 0.51 |
 Aspirin | 17 (43) | 11 (28) | 0.14 |
Blood pressure, mean (s.d.) | |||
 Systolic blood pressure, mmHg | 130 (29) | 130 (18) | 0.33 |
 Diastolic blood pressure, mmHg | 77 (13) | 81 (12) | 0.12 |
 Heart rate, bpm, mean (s.d.) | 72 (13) | 75 (13) | 0.56 |
Baseline serum measurements, median (IQR) | |||
 Creatinine, μmol/L | 715 (559–840) | 787 (568–925) | 0.38 |
 N-Terminal brain natriuretic peptide, ng/mL | 1487 (741–2535) | 889 (554–1368) | 0.28 |
 Hemoglobin, g/L | 114 (105–129) | 119 (109–127) | 0.54 |
 C-reactive protein, ng/mL | 2.9 (1.9–7.6) | 1.5 (1.0–4.2) | 0.019 |
 Growth differentiation factor-15, pg/mL | 5440 (4307–6452) | 4744 (3639–5784) | 0.13 |
 PTH, pmol/mL | 32 (18–67) | 36 (19–79) | 0.79 |
Cardiovascular magnetic resonance parameters, mean (s.d.) | |||
 LVEDVi (mL/m2) | 84 (22) | 94 (24) | 0.038 |
 LVESVi (mL/m2) | 34 (13) | 40 (15) | 0.043 |
 LVEF (%) | 59.8 (6.6) | 57.6 (6.4) | 0.13 |
 LVMi (g/m2) | 65.1 (20) | 66.7 (20) | 0.78 |
 Cardiac index (L/min/m2) | 3.49 (0.9) | 3.96 (0.9) | 0.024 |
 GLS (%) | −16.6 (3.2) | −15.9 (3.0) | 0.44 |
 GCS (%) | −19.7 (3.6) | −18.1 (3.4) | 0.057 |
 GRS (%) | 46.1 (13) | 40.8 (11) | 0.082 |